ReviewJournal of blood medicine2021
Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers.
Review in Journal of blood medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.American journal of hematology · 2025Trial
- Trial
- Evolution of Hemophilia Management in Italy: Results from a Delphi Consensus Study.Journal of clinical medicine · 2026Article
- Second-Look Arthroscopy Revealing Cartilage Coverage Following Arthroscopic Synovectomy in Severe Hemophilic Arthropathy of the Knee: A Case Report.Clinical case reports · 2026Article
- Feasibility of the photoacoustic detection of haemophilia-related microbleeds: a preclinical study using isolated pig limbs.Thrombosis journal · 2026Article
- Genotype-Specific Postural Control Deficits in Hemophilia A: Insights from Center of Pressure Analysis Beyond Radiographic Arthropathy.International journal of molecular sciences · 2026Article
- Factors contributing to the development of hemophilic arthropathy: A real-world study.Annals of hematology · 2026Article
- Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting.Therapeutic advances in hematology · 2026Article
- Normalization of Haemostasis in People with Haemophilia A: Expert Consensus on Unmet Needs and a Framework for Advancing Towards Health Equity.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis.Therapeutic advances in hematology · 2026Article
- Hemosiderin quantification in hemophilic arthropathy using quantitative magnetic resonance imaging.Scientific reports · 2025Article
- Impact of Systematic Joint Examination (Ultrasound, Functional and Physical) on Treatment Management Decisions in Patients With Haemophilia A in France: Final Data From the Prospective, Observational A-MOVE Study.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Observational
- Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study.Journal of blood medicine · 2025Article
- Assessment of joint health in females with haemophilia: The carriers ultrasound project (CUP) study.Haemophilia : the official journal of the World Federation of Hemophilia · 2024Article
- Infrared thermography: An investigative tool for detection of subclinical bleed in hemophilia on prophylaxis.The Indian journal of medical research · 2024Article
- Comparison between natural rubber knee support and sponge knee support on the protection of knee joint: A crossover randomized controlled study among patients with bleeding disorders.Health science reports · 2024Article
- Walking ability in adults with severe hemophilia: A cross-sectional study.Clinical hematology international · 2024Article
- Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials.Current protein & peptide science · 2024Review
- Simoctocog alfa (NuwiqTherapeutic advances in hematology · 2024Review
- Blood-Induced Arthropathy: A Major Disabling Complication of Haemophilia.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Joint health is a key contributor to quality of life in patients with hemophilia. However, variables that impact long-term joint outcomes have not been comprehensively defined. A systematic literature search identified publications relating to joint health in patients with hemophilia. Studies clearly show that early, sustained prophylaxis with factor replacements improves long-term joint outcomes. However, a subset of patients appear to develop arthropathy despite maintaining excellent bleeding outcomes, which suggests possible recurrent asymptomatic bleeding into the joints in these patients. Furthermore, limited data are available on how long-acting factor VIII and factor IX replacement therapies could impact long-term joint outcomes. Many variables were identified as potential indicators that a patient may develop hemophilic arthropathy, including genetic mutations, endogenous factor VIII and IX levels, bone health, and physical activity levels. Tools for the diagnosis and monitoring of hemophilic arthropathy are critical to detect early joint damage, so that management can be adjusted accordingly. Imaging techniques, particularly magnetic resonance imaging, can detect synovial changes, a strong predictor for the future development of hemophilic arthropathy. In addition, several biomarkers associated with cartilage and bone formation, vascularization, and angiogenesis could potentially identify the onset and progression of early joint damage. Since the development of hemophilic arthropathy is complex, a comprehensive therapeutic approach is necessary for the effective prevention of arthropathy in patients with hemophilia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.